Business
Admission to trading and first day of dealings
Admission to trading and first day of dealings.
About this update from Probiotix Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6567G\n Probiotix Health PLC\n 31 March 2022\n \n \n \n \n ProBiotix Health plc\n (\"ProBiotix Health\" or the \"Company\")\n \n Admission to trading on AQSE and first day of dealings\n \n ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces that 121,666,666 ordinary shares of 0.05p each in the Company (\"Ordinary Shares\") are today being admitted to trading on the Access Segment of the AQSE Growth Market (\"Admission\"). \n \n \n \n \n \n In connection with Admission, ProBiotix Health has raised £2.5 million through a placing and subscription of 11,904,762 Ordinary Shares at a price of 21p per share. \n \n \n \n The Directors of ProBiotix Health believe that an investment in the Company represents an opportunity to invest in an innovative technology that is underpinned by a significant portfolio of Intellectual Property Rights, supported by an experienced board, and applicable to a range of markets.\n \n \n \n Key information:\n \n \n · ProBiotix Health is the holding company of ProBiotix Limited (\"ProBiotix\").\n \n · \n ProBiotix was established by AIM-listed OptiBiotix Health plc (\"OptiBiotix\"), a global leader in microbiome modulating compounds for use in functional foods and supplements, to develop probiotics to tackle cardiovascular disease and other lifestyle conditions. \n \n \n ·\n The Company's strategy is to develop next-generation microbiome solutions for a wide range of health conditions and to deliver commercially successful products supported by a strong scientific evidence base. \n \n \n · \n Since its creation, ProBiotix has made considerable progress and has successfully transitioned from a research and development specialist into a profitable commercial organisation whose products are being commercialised in over 60 countries. \n \n \n ·Human volunteer studies have shown that ProBiotix's principal product, Lactobacillus plantarum ECGC13110402 (\"LP-LDL®\"), can reduce key cardiovascular risk markers, such as total cholesterol, LDL (bad) cholesterol, and Apolipo protein B, by up to 34.2 per cent, 28.4 per cent and 28.6 per cent respectively.\n \n · ProBiotix commercialises LP-LDL® as an ingredient and i...